Provista is developing transformational diagnostic tests
to radically change the way women's cancers are detected and managed. For the better.
Provista Diagnostics is focused on developing world-class diagnostics for indications in breast and gynecologic cancers. When used in combination with imaging our proteomic tests provide more robust evidence for detection and treatment decisions.
Provista's advanced proprietary ProteoMark™ Technology combines multiple serum protein biomarkers and tumor associated autoantibodies with specific patient data and statistical modeling to yield highly accurate diagnostic tests for women's cancers.
Provista is developing a robust pipeline of proprietary blood-based molecular diagnostic tests to address the unmet needs in women's cancers, including breast, ovarian, endometrial and HPV-associated cancers.